医学
心力衰竭
肥厚性心肌病
内科学
心脏病学
基因型
心肌病
心源性猝死
梅德林
扩张型心肌病
作者
Athanasios Bakalakos,Alexandros Protonotarios,Menelaos Pavlou,Douglas Ewan Cannie,Rebeca Lorca,CAROLINE J. COATS,Emanuele Monda,Konstantinos Savvatis,Luís Rocha Lopes,Constantinos O’Mahony,Juan Pablo Kaski,Massimiliano Lorenzini,Petros Syrris,Perry M Elliot
标识
DOI:10.1016/j.jchf.2026.103149
摘要
Background Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by left ventricular hypertrophy and progression to heart failure (HF). Approximately 40% of cases are caused by variants in genes encoding sarcomere proteins. Objectives This study sought to determine the relationship between genotype and other clinical predictors of HF outcomes in HCM patients. Methods This observational, single-center cohort comprised 505 genotyped HCM patients (52 years of age [Q1-Q3: 41-62 years], 33% women). Patients were stratified into gene-positive (G+) and gene-elusive (G−) groups. The primary endpoint was HF-related death or cardiac transplantation. Secondary endpoints included cardiac death, arrhythmic events, and all-cause mortality. Proportional hazards models were used to evaluate predictors of outcomes, including genetic status, log-transformed N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, peak VO 2 , and left ventricular ejection fraction (LVEF). Results During a median follow-up of 10.6 years (Q1-Q3: 4.6-15.0 years), 34 patients (6.7%) experienced the primary outcome (HF-related death: 22 [4.4%] and heart transplantation: 12 [2.4%]). The HF endpoint occurred in 12.8% (28 of 219) of the G+ group compared with 2.1% (6 of 286) of the G− group. In multivariable Cox analysis, G+ status (HR: 5.86; 95% CI: 2.26-15.25; P < 0.001), log NT-proBNP (HR: 2.46; 95% CI: 1.59-3.80; P < 0.001), peak VO 2 (HR: 0.90; 95% CI: 0.82-0.98; P < 0.001), and LVEF (HR: 0.74 per 5% increment; 95% CI: 0.63-0.86; P < 0.001) were independently associated with HF outcomes. For secondary endpoints, 60 patients (11.9%) died of cardiac causes, 34 (6.7%) experienced arrhythmic events, and 115 (22.8%) died of any cause. Conclusions Genetic status, peak VO 2 , log NT-proBNP, and LVEF independently predict HF outcomes in HCM. Combining genotype with HF biomarkers and functional capacity measures identifies patients at increased risk of HF-related death or transplant and may support targeted monitoring and selection for disease-modifying trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI